The UDIC will shortly begin a clinical trial to evaluate the subcutaneous administration of levodopa, through continuous perfusion, to treat motor fluctuations in advanced Parkinson’s. For the first time, this use of an “ultra concentrated” levodopa that can allow its subcutaneous administration. The use of a continuous infusion pump can obtsin an adequate control of the severe motor blocks that our patients suffer.
Related Stories
21 de November de 2023
Trial on LRRK2 mutation in Parkinson’s disease is about to be completed. Our Clinical Trials…
Posted in: Uncategorised
16 de January de 2023
On Epiphany, the U.S. Food and Drug Administration approved a new drug for early-stage Alzheimer’s…
3 de June de 2021
The General University Hospital of Catalonia is the first recognized center in Europe to evaluate…
Posted in: Alzeimer, Uncategorised
22 de July de 2020
The FDA has approved the use of sublingual apomorphine (KYNMOBI) in motor blocks, in Parkinson’s…
Posted in: Parkinson, Uncategorised
12 de December de 2019
5 de November de 2019
The Pasqual Maragall Foundation develops a method based on magnetic resonance imaging It allows to…
Posted in: Alzeimer, Uncategorised
19 de July de 2019
We have been selected to evaluate an innovative therapy in this terrible disease. We will…
Posted in: Uncategorised